On Monday, Shares of Pfizer Inc. (NYSE:PFE), gained 1.18% to $33.47.
Pfizer, declared the final results of its formerly declared offers to exchange any and all validly tendered and accepted notes of each series listed in the table below (collectively, the “Hospira Notes”) issued by Hospira, Inc., a recently attained partner of Pfizer, for new notes to be issued by Pfizer (collectively, the “Pfizer Notes”), and the related solicitations of consents to amend the indenture governing the Hospira Notes and the Hospira Notes (together, the “Exchange Offers”). A Registration Statement on Form S-4 (File No. 333-206758) (the “Registration Statement”) regarding the issuance of the Pfizer Notes was filed with the Securities and Exchange Commission (“SEC”) on September 3, 2015, was amended by Amendment No. 1 to the Registration Statement filed with the SEC on September 16, 2015, and was declared effective by the SEC on September 25, 2015.
As of 11:59 p.m., New York City time, on October 1, 2015 (the “Expiration Date”), the aggregate principal amounts listed in the table below of each series of Hospira Notes had been validly tendered and not validly withdrawn following the terms and conditions of the Exchange Offers. The final settlement of the Exchange Offers is predictable to take place on or about October 5, 2015.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others.
Shares of Abbott Laboratories (NYSE:ABT), inclined 0.02% to $41.39, during its last trading session.
In its second year as an Official Sponsor of the Bank of America Chicago Marathon, Abbott (ABT) will again demonstrate its commitment to assisting people achieve their aims through good health. From practiced runners and wheelchair racers to first-time participants, marathons prove that when people are at their healthiest, they can do more, achieve more and experience more in life.
Abbott’s sponsorship of the 2015 Bank of America Chicago Marathon, which takes place in the global healthcare company’s hometown, complements its title sponsorship of the Abbott World Marathon Majors (AWMM). Since announcing its AWMM sponsorship at the same race last year, Abbott has celebrated and supported tens of thousands of marathon participants at the Tokyo Marathon, the Boston Marathon, the Virgin Money London Marathon and the BMW Berlin-Marathon. Next month, Abbott will celebrate people living active, healthy lives at the TCS New York City Marathon – the sixth iconic race in the AWMM series.
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products.
Shares of Vereit Inc (NYSE:VER), inclined 4.38% to $8.11, during its last trading session.
Vereit, declared that Michael J. Bartolotta, CPA, has been named Executive Vice President, Chief Financial Officer and Treasurer effective October 5, 2015.
Mr. Bartolotta most recently served as Executive Vice President and CFO for global real estate services firm Cushman & Wakefield. A 35-year veteran of the commercial real estate and financial industries, Mr. Bartolotta has extensive experience in administration, business leadership and working with boards of directors, financial institutions and investors, in addition to an established track record of success in improving finance, IT and general business operations.
Additionally, Mr. Rufrano declared administration re-positioning that aligns with VEREIT’s focus on being a full-service real estate operating company. Thomas W. Roberts has been named Executive Vice President and Chief Investment Officer and Paul McDowell will serve as Executive Vice President and Chief Operating Officer for the Company’s real estate segment. Messrs. Roberts and McDowell had been serving as VEREIT’s Co-Heads of Real Estate.
VEREIT, Inc., formerly American Realty Capital Properties, Inc., is a real estate operating company. The Company owns and manages a diversified portfolio of retail, restaurant, office and industrial real estate assets, including approximately 4,645 properties totaling 101.8 million square feet. In addition, the Company manages real estate investments on behalf of the Cole Capital non-traded real estate investment trust (REITs).
Finally, Cerner Corporation (NASDAQ:CERN), ended its last trade with 1.27% gain, and closed at $62.12.
Cerner, a global leader in health care technology, and the Society of Hospital Medicine (SHM) declared the integration of SHM’s Project BOOST(TM) toolkit into Cerner’s Readmission Prevention Solution, available within the Cerner Millennium(R) electronic health record (EHR).
The integration of Project BOOST into Cerner Millennium provides clinicians with a comprehensive intervention strategy to optimize the patient discharge process. Developed by a panel of expert clinicians, Project BOOST content embedded into clinical workflows comprises:
- Automated early identification of specific readmission risk factors and corresponding interventions
- General Assessment of Preparedness checklist to assist identify patient concerns about their readiness to leave the hospital
- Simplified patient-centered discharge instructions to assist safely transition a patient home
- Teach Back education process and documentation to assist patients comprehend pertinent information related to their hospitalization and transition
Cerner Corporation (Cerner) is a supplier of health care information technology (HCIT). The Company offers a range of intelligent solutions and services that support the clinical, financial and operational needs of organizations. The Company offers software, hardware, professional services and managed services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
